Real-world experience for the outcomes and costs of treating hepatitis C patients: Results from the German Hepatitis C-Registry (DHC-R).

Authors:
Krüger K; Rossol S; Krauth C; Buggisch P; Mauss S and 5 more

Journal:
Z Gastroenterol

Publication Year: 2022

DOI:
10.1055/a-1852-5713

PMCID:
PMC10162862

PMID:
35839795

View on PubMed View on PMC View Publisher
Journal Information

Full Title: Z Gastroenterol

Abbreviation: Z Gastroenterol

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Gastroenterology

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Related Papers from Same Journal
Liver transplantation for HCC in cirrhosis: Are Milan criteria outdated?
Gundlach JP; Ellrichmann M; van Rosmalen M and 8 more (2024) - Transparency Score: 2/6
Living-Donor Liver Transplantation for a Large Hepatocellular Carcinoma in a Genetically Identical …
Koek G; Schmitz SM; Bednarsch J and 7 more (2024) - Transparency Score: 3/6
Immune-mediated Gastritis in a Patient with metastatic Lung Cancer due to Therapy with the immune C…
Ecker ME; Weckauf H; Tebbe S and 1 more (2023) - Transparency Score: 2/6
Validation of the German version of the Short Health Scale - a brief, valid and reliable instrument…
Demmer S; Kleindienst N; Hjortswang H and 4 more (2023) - Transparency Score: 4/6
Colorectal cancer surveillance by colonoscopy in a prospective, population-based long-term Swiss sc…
Zgraggen A; Stoffel ST; Barbier MC and 1 more (2022) - Transparency Score: 3/6
View All Papers from This Journal
Transparency Score
3/6
50.0% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Data Sharing
Code Sharing
Evidence found in paper:

"Conflict of Interest The authors declare that they have no conflict of interest."

Evidence found in paper:

"The German Hepatitis C-Registry is financially supported by AbbVie Deutschland GmbH & Co. KG, Gilead Sciences GmbH, MSD Sharp & Dohme GmbH as well as Bristol-Myers Squibb GmbH & Co. KGaA and Janssen-Cilag GmbH (each until 2020-07-14) and Roche Pharma AG (until 2017-07-14)."

Protocol Registration
Open Access
Paper is freely available to read
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025